These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36702680)

  • 1. Futibatinib (Lytgobi) for cholangiocarcinoma.
    Roskoski R
    Trends Pharmacol Sci; 2023 Mar; 44(3):190-191. PubMed ID: 36702680
    [No Abstract]   [Full Text] [Related]  

  • 2. Futibatinib (Lytgobi) for cholangiocarcinoma.
    Med Lett Drugs Ther; 2023 Apr; 65(1674):e69-e70. PubMed ID: 37039618
    [No Abstract]   [Full Text] [Related]  

  • 3. Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma.
    Khoury R; Chahine C; Ibrahim R; Khalife N; Saleh M; Saleh K
    Future Oncol; 2023 Jun; 19(17):1161-1163. PubMed ID: 37293779
    [No Abstract]   [Full Text] [Related]  

  • 4. Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma.
    Lamarca A; Vogel A
    ESMO Open; 2023 Dec; 8(6):102049. PubMed ID: 37922686
    [No Abstract]   [Full Text] [Related]  

  • 5. [Futibatinib for cholangiocarcinomas with a FGFR2 fusion or rearrangement, locally advanced or metastatic].
    Noé C; Edeline J
    Bull Cancer; 2023 Oct; 110(10):985-986. PubMed ID: 37500387
    [No Abstract]   [Full Text] [Related]  

  • 6. Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer.
    De SK
    Curr Med Chem; 2024; 31(6):666-670. PubMed ID: 37062061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Futibatinib: First Approval.
    Syed YY
    Drugs; 2022 Dec; 82(18):1737-1743. PubMed ID: 36441501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.
    Takenaka M; Akiba J; Kawaguchi T; Niizeki T; Arinaga-Hino T; Sata M; Nakashima O; Yano H; Kage M
    Pathol Int; 2013 Apr; 63(4):233-5. PubMed ID: 23692426
    [No Abstract]   [Full Text] [Related]  

  • 9. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASO Author Reflections: Usage of Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma.
    Holster JJ; Groot Koerkamp B
    Ann Surg Oncol; 2022 Sep; 29(9):5539-5540. PubMed ID: 35266080
    [No Abstract]   [Full Text] [Related]  

  • 11. Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma.
    Hoy SM
    Target Oncol; 2024 May; 19(3):473-480. PubMed ID: 38724820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible role of ginseng as an additional therapy for cholangiocarcinoma therapy: A discussion on the role of vimentin suppression.
    Sookaromdee P; Wiwanitkit V
    J Cancer Res Ther; 2023; 19(5):1492. PubMed ID: 37787343
    [No Abstract]   [Full Text] [Related]  

  • 13. Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis?
    Stefanini B; Tonnini M; Marseglia M; Tovoli F
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):887-889. PubMed ID: 35866267
    [No Abstract]   [Full Text] [Related]  

  • 14. Highlights of topic "Biochemical and molecular pathological aspects of cholangiocarcinoma".
    Murakami Y
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):359-61. PubMed ID: 24840727
    [No Abstract]   [Full Text] [Related]  

  • 15. Adrenal metastasis from intrahepatic cholangiocarcinoma.
    Pandey D; Lee KH; Wong SY; Tan KC
    Liver Int; 2007 Sep; 27(7):1016. PubMed ID: 17696942
    [No Abstract]   [Full Text] [Related]  

  • 16. Nivolumab for treating patients with occupational cholangiocarcinoma.
    Tanaka S; Umemoto K; Kubo S; Sato Y; Mimaki S; Tsuchihara K; Takemura S; Shinkawa H; Mori A; Ikeda M
    J Hepatobiliary Pancreat Sci; 2022 Nov; 29(11):1153-1155. PubMed ID: 35793385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
    Chung V
    Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
    Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Sporadic Case of Advanced Metastatic Cholangiocarcinoma in a Child: A Case Report and Review of Literature.
    Hall C; Mamlok V; Al-Khalil I
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):e333-5. PubMed ID: 25851556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.
    Uson Junior PLS; Borad MJ
    Expert Opin Investig Drugs; 2022 Jan; 31(1):125-131. PubMed ID: 34904492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.